Search results
Results from the WOW.Com Content Network
The first time Horowitz tried to wean off of Lexapro, forums helped connect him to “thousands of people who had the exact same experience as me. They had the extreme symptoms that I did—I ...
Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. [13] It is also sometimes used off-label for treatment of chemotherapy-induced nausea and vomiting [ 14 ] and as an appetite stimulant . [ 15 ]
Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI).
In general, contraindications to antipsychotic switching are cases in which the risk of switching outweighs the potential benefit. Contraindications to antipsychotic switching include effective treatment of an acute psychotic episode, patients stable on a LAI antipsychotic with a history of poor adherence, and stable patients with a history of self-injurious behavior, violent behavior, or ...
Moving forward. Jana Kramer revealed that she was able to stop taking anxiety medication for the first time in nearly 20 years. Anne Hathaway, Kendall Jenner and More Stars Open Up About Anxiety ...
Benzodiazepine withdrawal syndrome (BZD withdrawal) is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.
Eventually I would like to wean off, but for now I'm so grateful for the miracle of medicine. It has allowed me to finally enjoy motherhood in the way I always dreamed of.
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...